scholarly journals Symptomatic and Asymptomatic Respiratory Viral Infections in the First Year of Life: Association With Acute Otitis Media Development

2014 ◽  
Vol 60 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Tasnee Chonmaitree ◽  
Pedro Alvarez-Fernandez ◽  
Kristofer Jennings ◽  
Rocio Trujillo ◽  
Tal Marom ◽  
...  
2008 ◽  
Vol 101 (11) ◽  
pp. 1722-1726 ◽  
Author(s):  
Samuli Rautava ◽  
Seppo Salminen ◽  
Erika Isolauri

A randomised, double-blind, placebo-controlled study was conducted to determine whether probiotics might be effective in reducing the risk of infections in infancy. Infants requiring formula before the age of 2 months were recruited from community well-baby clinics. Infant formula supplemented with the probioticsLactobacillus rhamnosusGG andBifidobacterium lactisBb-12 or placebo was administered daily until the age of 12 months. Incidence of early infections (before the age of 7 months) and incidence of recurrent (three or more) infections during the first year of life were recorded as the main outcome measures of the study. During the first 7 months of life, seven out of thirty-two (22 %) infants receiving probiotics and twenty out of forty (50 %) infants receiving placebo experienced acute otitis media (risk ratio (RR) 0·44 (95 % CI 0·21, 0·90);P = 0·014) and antibiotics were prescribed for ten out of thirty-two (31 %) infants receiving probiotics and twenty-four out of forty (60 %) infants receiving placebo (RR 0·52 (95 % CI 0·29, 0·92);P = 0·015). During the first year of life, nine out of thirty-two (28 %) infants receiving probiotics and twenty-two out of forty (55 %) infants receiving placebo encountered recurrent respiratory infections (RR 0·51 (95 % CI 0·27, 0·95);P = 0·022). These data suggest that probiotics may offer a safe means of reducing the risk of early acute otitis media and antibiotic use and the risk of recurrent respiratory infections during the first year of life. Further clinical trials are warranted.


2014 ◽  
Vol 99 (Suppl 2) ◽  
pp. A286.3-A286
Author(s):  
S Diacova ◽  
A Jivalcovschi ◽  
E Antohi ◽  
T Macalet ◽  
O Diacova

2016 ◽  
Vol 1 (1) ◽  
pp. 114-117
Author(s):  
N. L. Kunelskaya ◽  
A. Y. Ivoylov ◽  
M. I. Kulagina ◽  
V. R. Pakina ◽  
V. V. Yanovskiy ◽  
...  

ARVI (acute respiratory viral infections, also often called ARD - acute respiratory disease) is a group of diseases that are similar in character and mostly characterized by a pathology of the respiratory system. If the pathogen is not identified, the patient is usually diagnosed with ARD, since the agent is not necessarily a virus. In developed countries, 18% of children aged 1--4 years suffer from acute respiratory viral infections [1]. Children aged 3 to 14 years suffer from ARVI most often. At the same time, children in the first year of life are practically not affected by acute respiratory viral infections. This is contributed by passive immunity which is acquired at birth and maintained during the first months of life thanks to breastfeeding. Influenza and ARVI account for 90% of all infectious pathologies and are the second leading cause of death from infectious diseases [2]. Delayed influenza mortality during epidemics can reach 100 cases per 100 thousand people [3]. Influenza epidemics cause enormous economic damage: in Russia, it equals more than 20 billion rubles each year [4].


2020 ◽  
Vol 16 (34) ◽  
pp. 10-14
Author(s):  
M.S. Savenkova ◽  
◽  

The article presents the literature data on the homeopathic drug Aflubin use for the complex treatment of influenza and acute respiratory viral infections in children, the opportunity of its use in the epidemic period of respiratory diseases, as well as in the form of a preventive tool. Summarized data concerning the main properties of the drug. The ingredients that make up the drug, affect the reduction of intoxication and temperature symptoms, contribute to the relief of coughing and pain. Aflubin can be used in children starting from the first year of life


2017 ◽  
Vol 87 (2) ◽  
pp. 104-110
Author(s):  
Cristina Calvo ◽  
Isabel Aguado ◽  
María Luz García-García ◽  
Esther Ruiz-Chercoles ◽  
Eloisa Díaz-Martinez ◽  
...  

Author(s):  
Emilia Thomas ◽  
Janna-Maija Mattila ◽  
Pasi Lehtinen ◽  
Tytti Vuorinen ◽  
Matti Waris ◽  
...  

Abstract Background Although many infants with respiratory syncytial virus (RSV) infection are hospitalized, most infants are treated as outpatients. Limited data are available on the burden of RSV in outpatient infants. Methods In a prospective study, we enrolled 431 newborn infants and followed them for a 10-month period (September-June). During each respiratory illness, we examined the infants and obtained nasopharyngeal specimens for the detection of RSV. The parents completed daily symptom diaries throughout the study. Results Among 408 active participants, the seasonal incidence rate of RSV illness was 328.4 per 1000 (95% confidence interval [CI] 275.2-389.0). Infants with ≥1 sibling had a 1.9-fold higher incidence of RSV illness than those without (95% CI 1.3-2.8; P = .0007). Acute otitis media developed in 103 (76.9%) of 134 infants with RSV infection, and 95 (70.9%) were treated with antibiotics. Nine (6.7%) infants with RSV were hospitalized, for a seasonal incidence rate of RSV hospitalization of 22.1 per 1000 (95% CI 10.1-41.9). Conclusions The outpatient burden of RSV is heavy on infants during the first year of life. Acute otitis media is a frequent complication of RSV, and it should be included in cost-effectiveness analyses of prevention or treatment of RSV infections in infants.


PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0121572 ◽  
Author(s):  
Alexandre C. Fortanier ◽  
Roderick P. Venekamp ◽  
Marieke L. A. de Hoog ◽  
Cuno S. P. M. Uiterwaal ◽  
Anne C. van der Gugten ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document